Vestal Point Capital, LP
13F Reported Value
ⓘ$3.6B
Holdings
90
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Vestal Point Capital, LP disclosed 90 positions worth $3.6B in its Form 13F-HR for Q1 2026, led by $RVMD (Revolution Medicines, Inc.) at 6.5% of the equity portfolio, followed by $BMRN and $ABVX. During the quarter the fund opened 37 new positions and exited 23 — including a new stake in $NBIX and a full exit from $QQQ. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from Vestal Point Capital, LP’s Form 13F-HR filing with the SEC under CIK 1974915.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$231.0M2,375,000 sh - 74.1#167
Quality
$202.0M3,575,000 sh - —
Quality
$167.0M1,500,000 sh - 75.4
Quality
$164.7M1,250,000 sh - 74.4
Quality
$142.6M2,275,000 sh - —
Quality
$127.4M3,250,000 sh - 54.1
Quality
$109.0M925,000 sh - —
Quality
$107.9M5,425,000 sh - 13.2
Quality
$100.8M6,500,000 sh - —
Quality
$92.6M1,100,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Revolution Medicines, Inc.$RVMD | — | $231.0M | 2,375,000 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 74.1#167 | $202.0M | 3,575,000 |
 Abivax S.A.$ABVX | — | $167.0M | 1,500,000 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 75.4 | $164.7M | 1,250,000 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 74.4 | $142.6M | 2,275,000 |
 Enliven Therapeutics, Inc.$ELVN | — | $127.4M | 3,250,000 |
 REPLIGEN CORP$RGEN | 54.1 | $109.0M | 925,000 |
 Bicara Therapeutics Inc.$BCAX | — | $107.9M | 5,425,000 |
 Nurix Therapeutics, Inc.$NRIX | 13.2 | $100.8M | 6,500,000 |
 Apogee Therapeutics, Inc.$APGE | — | $92.6M | 1,100,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Vestal Point Capital, LP's 90 positions.
Showing top 10 of 90 holdings.
Sector Allocation
Healthcare
$3.5B
Technology
$29.8M
Full Holdings — Vestal Point Capital, LP (Q1 2026)
All 90 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RVMD | Revolution Medicines, Inc. | $231.0M | 6.5% | +705% | — |
| 2 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $202.0M | 5.7% | +19% | 74.1 |
| 3 | $ABVX | Abivax S.A. | $167.0M | 4.7% | -21% | — |
| 4 | $NBIX | NEUROCRINE BIOSCIENCES INC | $164.7M | 4.6% | NEW | 75.4 |
| 5 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $142.6M | 4.0% | +153% | 74.4 |
| 6 | $ELVN | Enliven Therapeutics, Inc. | $127.4M | 3.6% | -15% | — |
| 7 | $RGEN | REPLIGEN CORP | $109.0M | 3.0% | +1014% | 54.1 |
| 8 | $BCAX | Bicara Therapeutics Inc. | $107.9M | 3.0% | +52% | — |
| 9 | $NRIX | Nurix Therapeutics, Inc. | $100.8M | 2.8% | +39% | 13.2 |
| 10 | $APGE | Apogee Therapeutics, Inc. | $92.6M | 2.6% | +100% | — |
| 11 |  $ASND | Ascendis Pharma A/S | $85.8M | 2.4% | +114% | 41.5 |
| 12 |  $IMCR | Immunocore Holdings plc | $83.4M | 2.3% | +373% | — |
| 13 |  $TSHA | Taysha Gene Therapies, Inc. | $80.5M | 2.3% | +31% | 4.1 |
| 14 |  $DYN | Dyne Therapeutics, Inc. | $72.5M | 2.0% | +3233% | — |
| 15 |  $SNY | Sanofi | $67.5M | 1.9% | NEW | — |
| 16 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $66.9M | 1.9% | +212% | 37.2 |
| 17 |  $SRRK | Scholar Rock Holding Corp | $65.1M | 1.8% | +89% | — |
| 18 |  $IMTX | Immatics N.V. | $60.8M | 1.7% | +1% | — |
| 19 |  $BMY | BRISTOL MYERS SQUIBB CO | $60.6M | 1.7% | +300% | 70.1 |
| 20 |  $ALC | ALCON INC | $60.3M | 1.7% | -28% | — |
| 21 |  $GLUE | Monte Rosa Therapeutics, Inc. | $59.3M | 1.7% | +365% | 18.1 |
| 22 |  $VERA | Vera Therapeutics, Inc. | $55.0M | 1.5% | +149% | — |
| 23 |  $TERN | Terns Pharmaceuticals, Inc. | $52.7M | 1.5% | -78% | — |
| 24 |  $GMED | GLOBUS MEDICAL INC | $52.6M | 1.5% | -52% | 77.6 |
| 25 |  $BSX | BOSTON SCIENTIFIC CORP | $50.2M | 1.4% | NEW | 79.9 |
| 26 |  $NUVL | Nuvalent, Inc. | $49.4M | 1.4% | +947% | — |
| 27 |  $COGT | Cogent Biosciences, Inc. | $47.4M | 1.3% | NEW | — |
| 28 |  $ANRO | Alto Neuroscience, Inc. | $46.4M | 1.3% | -17% | — |
| 29 |  $RAPP | Rapport Therapeutics, Inc. | $44.9M | 1.3% | +29% | — |
| 30 |  $IRON | Disc Medicine, Inc. | $44.8M | 1.3% | -5% | — |
| 31 |  $UTHR | UNITED THERAPEUTICS Corp | $44.5M | 1.2% | NEW | 80.1 |
| 32 |  $CLDX | Celldex Therapeutics, Inc. | $38.8M | 1.1% | +5% | 13.2 |
| 33 |  $KALV | KalVista Pharmaceuticals, Inc. | $37.2M | 1.0% | -2% | 25.9 |
| 34 |  $XENE | Xenon Pharmaceuticals Inc. | $37.2M | 1.0% | +7% | 12.9 |
| 35 |  $SLDB | Solid Biosciences Inc. | $36.0M | 1.0% | -14% | — |
| 36 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $35.9M | 1.0% | NEW | — |
| 37 |  $PTGX | Protagonist Therapeutics, Inc | $34.4M | 1.0% | NEW | 24.8 |
| 38 |  $DNLI | Denali Therapeutics Inc. | $34.0M | 0.9% | +281% | — |
| 39 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $30.9M | 0.9% | NEW | 75.1 |
| 40 |  $WAT | WATERS CORP /DE/ | $29.8M | 0.8% | NEW | 69.9 |
| 41 |  $VKTX | Viking Therapeutics, Inc. | $29.7M | 0.8% | NEW | — |
| 42 |  $INSP | Inspire Medical Systems, Inc. | $27.8M | 0.8% | NEW | 46 |
| 43 |  $CBIO | CRESCENT BIOPHARMA, INC. | $27.6M | 0.8% | +0% | 28 |
| 44 |  $TRVI | Trevi Therapeutics, Inc. | $25.8M | 0.7% | NEW | — |
| 45 |  $LXEO | Lexeo Therapeutics, Inc. | $25.7M | 0.7% | +0% | — |
| 46 |  $SLNO | SOLENO THERAPEUTICS INC | $24.4M | 0.7% | NEW | 46.3 |
| 47 |  $BBNX | Beta Bionics, Inc. | $22.2M | 0.6% | +269% | 22.8 |
| 48 |  $NKTR | NEKTAR THERAPEUTICS | $20.5M | 0.6% | NEW | 10.2 |
| 49 |  $CYTK | CYTOKINETICS INC | $19.8M | 0.6% | NEW | 28 |
| 50 |  $AZN | ASTRAZENECA PLC | $19.7M | 0.6% | NEW | — |
| 51 |  $WST | WEST PHARMACEUTICAL SERVICES INC | $18.8M | 0.5% | NEW | 66.8 |
| 52 |  $GEHC | GE HealthCare Technologies Inc. | $17.8M | 0.5% | NEW | 58.2 |
| 53 |  $SGP | SpyGlass Pharma, Inc. | $17.3M | 0.5% | NEW | — |
| 54 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $17.2M | 0.5% | +27% | 64.9 |
| 55 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $16.5M | 0.5% | NEW | 25.4 |
| 56 |  $WGS | GeneDx Holdings Corp. | $16.1M | 0.5% | NEW | 38.6 |
| 57 |  $DMRA | Damora Therapeutics, Inc. | $15.5M | 0.4% | NEW | — |
| 58 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $15.2M | 0.4% | +38% | 26.3 |
| 59 |  $ENGN | enGene Therapeutics Inc. | $14.7M | 0.4% | +105% | — |
| 60 |  $SVRA | Savara Inc | $14.2M | 0.4% | +62% | — |
| 61 |  $TARS | Tarsus Pharmaceuticals, Inc. | $14.0M | 0.4% | NEW | 40.8 |
| 62 |  $VYGR | Voyager Therapeutics, Inc. | $11.6M | 0.3% | +104% | 5.5 |
| 63 |  $PODD | INSULET CORP | $10.6M | 0.3% | NEW | 70.4 |
| 64 |  $TECX | Tectonic Therapeutic, Inc. | $10.1M | 0.3% | +0% | — |
| 65 |  $SRZN | Surrozen, Inc./DE | $9.9M | 0.3% | NEW | — |
| 66 |  $ARVN | ARVINAS, INC. | $9.6M | 0.3% | NEW | 13.9 |
| 67 |  $MPLT | MapLight Therapeutics, Inc. | $8.5M | 0.2% | +9% | — |
| 68 |  $FULC | Fulcrum Therapeutics, Inc. | $8.4M | 0.2% | +16% | — |
| 69 |  $OKUR | OnKure Therapeutics, Inc. | $7.6M | 0.2% | +190% | — |
| 70 |  $MYGN | MYRIAD GENETICS INC | $7.4M | 0.2% | +35% | 30.2 |
| 71 |  $OLMA | Olema Pharmaceuticals, Inc. | $6.4M | 0.2% | -74% | — |
| 72 |  $AVR | Anteris Technologies Global Corp. | $6.4M | 0.2% | NEW | — |
| 73 |  $QURE | uniQure N.V. | $5.9M | 0.2% | NEW | — |
| 74 |  $CADL | Candel Therapeutics, Inc. | $5.5M | 0.1% | NEW | — |
| 75 |  $PALI | PALISADE BIO, INC. | $4.4M | 0.1% | NEW | — |
| 76 |  $VCYT | VERACYTE, INC. | $4.2M | 0.1% | NEW | 59.5 |
| 77 |  $ZBIO | Zenas BioPharma, Inc. | $3.9M | 0.1% | NEW | 14.4 |
| 78 |  $GERN | GERON CORP | $3.8M | 0.1% | -78% | — |
| 79 |  $MNPR | Monopar Therapeutics | $3.6M | 0.1% | NEW | — |
| 80 |  $ZURA | Zura Bio Ltd | $3.0M | 0.1% | NEW | — |
| 81 |  $NVCR | NovoCure Ltd | $2.7M | 0.1% | -52% | — |
| 82 |  $NYXH | Nyxoah SA | $2.5M | 0.1% | -22% | — |
| 83 |  $URGN | UroGen Pharma Ltd. | $2.5M | 0.1% | NEW | — |
| 84 |  $PASG | Passage BIO, Inc. | $2.4M | 0.1% | +0% | — |
| 85 |  $TYRA | Tyra Biosciences, Inc. | $2.1M | 0.1% | -98% | — |
| 86 |  $RGNX | REGENXBIO Inc. | $909,440 | 0.0% | +219% | 26.9 |
| 87 |  $TENX | TENAX THERAPEUTICS, INC. | $854,490 | 0.0% | +0% | — |
| 88 |  $MGNX | MACROGENICS INC | $809,200 | 0.0% | +0% | 31.7 |
| 89 |  $ABSI | Absci Corp | $696,657 | 0.0% | NEW | 4.4 |
| 90 |  $APRE | Aprea Therapeutics, Inc. | $267,015 | 0.0% | NEW | — |
New Positions (37)
$NBIX NEUROCRINE BIOSCIENCES INC$164.7M$SNY Sanofi$67.5M$BSX BOSTON SCIENTIFIC CORP$50.2M$COGT Cogent Biosciences, Inc.$47.4M$UTHR UNITED THERAPEUTICS Corp$44.5M$DRUG BRIGHT MINDS BIOSCIENCES INC.$35.9M$PTGX Protagonist Therapeutics, Inc$34.4M$REGN REGENERON PHARMACEUTICALS, INC.$30.9M$WAT WATERS CORP /DE/$29.8M$VKTX Viking Therapeutics, Inc.$29.7M$INSP Inspire Medical Systems, Inc.$27.8M$TRVI Trevi Therapeutics, Inc.$25.8M$SLNO SOLENO THERAPEUTICS INC$24.4M$NKTR NEKTAR THERAPEUTICS$20.5M$CYTK CYTOKINETICS INC$19.8MExited Positions (23)
$QQQPUT INVESCO QQQ TRUST, SERIES 1
$ACLX Arcellx, Inc.
$DXCM DEXCOM INC
$MRK Merck & Co., Inc.
$ABT ABBOTT LABORATORIES
$JAZZ Jazz Pharmaceuticals plc
$DAWN Day One Biopharmaceuticals, Inc.
$AXSM Axsome Therapeutics, Inc.
$LNTH Lantheus Holdings, Inc.
$ZYME Zymeworks Inc.
$UPB Upstream Bio, Inc.
$PEN Penumbra Inc
$GILD GILEAD SCIENCES, INC.
$DBVT DBV Technologies S.A.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Vestal Point Capital, LP including:
Track Vestal Point Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Vestal Point Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Vestal Point Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Vestal Point Capital, LP (SEC CIK: 1974915), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Vestal Point Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.